CLOVIS ONCOLOGY INC

NASDAQ: CLVS
$6.43
-$0.70 (-9.8%)
Closing price March 30, 2020
Wednesday's top analyst upgrades, downgrades and initiations included Agilent Technologies, American Power, Apache, Boeing, Ciena, Cisco, FireEye, Palo Alto Networks, Sony, Southwest Airlines and...
Lee Jackson
Tuesday's top analyst upgrades, downgrades and initiations included Apple, Blackstone, CBS, Global Payments, Netflix, Ralph Lauren, Walt Disney and Wynn Resorts.
Lee Jackson
The top analyst upgrades, downgrades and initiations on Tuesday included Advanced Micro Devices, Apple, Barrick Gold, Domino's Pizza, Intel, McDonald's, Occidental Petroleum and Salesforce.com.
Jon C. Ogg
The top analyst upgrades, downgrades and initiations seen on Friday included Shopify, Qualcomm, Pinterest, Sprouts Farmer's Market, BlackLine, Fortinet and Carbon Black.
Chris Lange
Clovis Oncology may have thought that it could sneak an announcement by late on Friday, but its shares were definitely paying the price Monday morning.
Chris Lange
Clovis Oncology shares jumped on Tuesday after the European Patent Office upheld the company’s claims.
Chris Lange
IBM, General Electric, McDermott International, and Clovis Oncology all posted new 52-week lows Wednesday.
Paul Ausick
The top analyst upgrades, downgrades and initiations seen on Wednesday included Aetna, Baker Hughes, Chesapeake Energy, Cognizant Technology Solutions, Cummins, Eli Lilly, General Electric, Qualcomm...
Jon C. Ogg
Keycorp, eBay, Schlumberger, and Clovis Oncology all posted new 52-week lows Monday.
Paul Ausick
Clovis Oncology shares dropped on Friday after the company announced initial data from its Phase 2 clinical trial of Rubraca at the ESMO 2018 Congress.
Chris Lange
Clovis Oncology shares jumped on Tuesday after the U.S. Food and Drug Administration (FDA) gave a critical update.
Chris Lange
Clovis shares might not be showing it now, but the company is facing some heat from the SEC over charges of misleading investors about the company’s developmental lung cancer drug.
Chris Lange
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
Chris Lange
Clovis Oncology shares saw a bump early on Thursday after the company announced that the European Medicines Agency has validated its application for a Type 2 variation to the marketing authorization...
Chris Lange
These are three totally different plays that all have huge upside potential for investors able to commit some of their more speculative capital to these trades.
Lee Jackson